Jean‐François Rossignol, Christian Bréchot – 29 March 2019 – Chronic infection by the hepatitis B virus (HBV) has remained a major public health problem. To achieve an HBV cure, we will likely need to combine antivirals with different viral targets as well as immunotherapy. Here, we report data from a pilot proof‐of‐concept clinical trial of nitazoxanide in treating chronic hepatitis B. Conclusion: Nitazoxanide offers novel mechanisms of antiviral activity, and it would be interesting to evaluate the potential of combining nitazoxanide with oral nucleos(t)ide analogues.

Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019

Laure Elkrief, José Ferrusquia‐Acosta, Audrey Payancé, Lucile Moga, Luis Tellez, Michael Praktiknjo, Bogdan Procopet, Oana Farcau, Victor De Lédinghen, Rustam Yuldashev, Nicolas Tabchouri, Louise Barbier, Jérôme Dumortier, Benjamin Menahem, Marta Magaz, Virginia Hernández‐Gea, Agustin Albillos, Jonel Trebicka, Laurent Spahr, Andrea De Gottardi, Aurélie Plessier, Dominique Valla, Laura Rubbia‐Brandt, Christian Toso, Christophe Bureau, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou, for VALDIG, an EASL consortium – 29 March 2019 – In patients with idiopathic noncirrhotic portal hypertension

Gavin Cloherty, Emily Butler, Mary Kuhns – 29 March 2019

Jessica G. Labadie, Manish Jain – 29 March 2019

28 March 2019

28 March 2019

Hannes Hagström, Catherine Williamson, Hanns‐Ulrich Marschall – 28 March 2019

Naim Alkhouri, Eric Lawitz, Mazen Noureddin – 28 March 2019 – Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide, and its aggressive form of nonalcoholic steatohepatitis (NASH) is becoming a leading cause for end‐stage liver disease and liver transplantation in the United States. In patients with NASH, the presence of advanced fibrosis is considered the most important prognostic factor in predicting liver‐related morbidity and mortality.

28 March 2019